ESTIMATE

 # FY17-18/PI/373

Phcog.Net
17, II Floor, Buddha Vihar Road
Cox Town
Bengaluru 560005
India
GSTIN 29AJQPM3638P1Z7

Bill To
Mr. Islamudin Ahmad
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Mulawarman University, Kampus UNMUL Samarinda 75119, East Kalimantan
Indonesia

Estimate Date : 06/08/2018
Expiry Date : 20/08/2018

#	Item & Description	Qty	Rate	Amount
1	Article Processing Charges- USD [PM_151_18]: Original Article: Isolation, Elucidation, and Molecular Docking Studies of Active Compounds from Phyllanthus niruri with Angiotensin Converting Enzyme Inhibition	1.00 1	550.00	550.00
			Sub Total	550.00
			Total	**$550.00**

Notes

Payment details
For Payment Via Credit Card/Debit Card
https://www.instamojo.com/phcognet/pharmacognosy-magazine/
(NOTE 550 USD = 38000 INR)

Terms & Conditions

Note:
1. All the charges of the Wire Transfer must be borne by you. You will have to state this in your Wire Transfer,.
2. Application with your bank _ that all the charges for the Wire Transfer to be debited to your Account. Once you send the Wire Transfer do not forget to send an email to me and billing@phcog.net with the details of the Wire Transfer.
3. Service tax is replaced by GST and currently charged at 18% for payments done within INDIA.
4. All disputes are subject to Bangalore Jurisdiction only.
5. This is system generated invoice and requires no signature.

Proofs corrections

Journal	Pharmacognosy Magazine
Article title	Isolation, Elucidation, and Molecular Docking Studies of Active Compounds from *Phyllanthus niruri* with Angiotensin-Converting Enzyme Inhibition
I would like to recheck the corrections:	Yes / No

If you have access to Acrobat, it may be helpful to mark the corrections in the PDF file using PENCIL and NOTE tools. Alternatively provide the list of corrections using this table. Please make the corrections' list self-explanatory and easy to understandable for a non-medical technical person.

List of corrections

Page number	Column (Left / Right)	Paragraph number from top	Line number from top of paragraph	Delete this text (Error)	Replace deleted text with (correction)
1	Pictorial Abstract (AQ4)			-	Has provided at the next page.
1	Left column (Introduction)	1	49-50	"….., mainly myocardialinfarction,atherosclerosis(i.e., hardeningofthearteries)…."	"….., mainly myocardial infarction, atherosclerosis (i.e., hardening of the arteries)…."
2,3,4,5, 6,7	Running title			ISLAMUDIN AHMAD, *et al.*: Angiotensin-Converting Enzyme Inhibitory Activity Isolated Compound from *P. niruri*	ISLAMUDIN AHMAD, *et al.*: Angiotensin-Converting Enzyme Inhibitory Activity of Isolated Compound from *P. niruri*

2	Left column	5 (Apparatus)	49-50	"…(Buchi,Germany),micropipettes100-1000µl(Eppendorf,Germany),aultravioletvisible(UV-VIS)spectrophotometer(Shimadzu,Japan),aUPLC-Qtof-HR-mass…"	"…(Buchi, Germany), micropipettes 100-1000 µl (Eppendorf, Germany), a ultra violet visible (UV-VIS) spectrophotometer (Shimadzu, Japan), a UPLC-Qtof-HR-mass…"
3	Table 1 (AQ5)				Ok

Pictorial Abstract



Isolation, Elucidation, and Molecular Docking Studies of Active Compounds from *Phyllanthus niruri* with Angiotensin Converting Enzyme Inhibition

ABSTRACT

Background: *Phyllanthus niruri*, in Indonesia is known as 'Meniran' has a long history of use in ethnic or traditional medicine worldwide, mainly as an antihypertensive agent. **Objective:** The present study was designed to isolate and identify active compounds with angiotensin-converting enzyme (ACE) inhibition activity from *P. niruri* herb and confirm the mechanism of action, affinity, and domain specificity interactions of the isolated compounds. **Materials and Methods:** Some fractions of *P. niruri* methanolic extract were subjected to column chromatography and preparative thin-layer chromatography to get active compounds. Structural elucidation was determined via spectroscopic methods. ACE inhibition activity was measured using hippuryl-L-histidyl-L-leucine (HHL) as a substrate ~~*in vitro*~~*in vitro* assay. Also, confirmation of the mechanism of action, affinity, and domain specificity interaction of the isolated compounds on ACE complex macromolecule (PDB id: 1O86) was performed by *in silico* molecular docking studies. **Results:** In this work, four active compounds were isolated from aerial part of *P. niruri*, including hypophyllantin (IC_{50} = 0.180 µg/mL), phyllantin (IC_{50} = 0.140 µg/mL), methyl gallate (IC_{50} = 0.015 µg/mL), and quercetin 3-*O*-β-D-glucopyranosyl-(1'''-6'')-α-rhamnoside (IC_{50} = 0.086 µg/mL). *In silico* molecular docking method emphasizes ligand-residue interactions, thereby predicting the inhibitory activity of these compounds. After docking to an ACE complex macromolecule, quercetin 3-*O*-β-D-glucopyranosyl-(1'''-6'')-α-rhamnoside obtained more interactions than lisinopril. **Conclusion:** The results were obtained from *in silico* and ~~*in vitro*~~*in vitro* experiments and confirm the potential active compound is an ACE inhibitor and a new antihypertensive agent.

Keywords: ACE inhibitors, Angiotensin-converting enzyme, Antihypertensive agent, Molecular docking, *Phyllanthus niruri*

Formatted: Justified, Line spacing: 1.5 lines

Formatted: Justified, Line spacing: 1.5 lines, Tab stops: 2.59 cm, Left

Formatted: Line spacing: 1.5 lines

Formatted: Font: (Default) Times New Roman, 12 pt

Formatted: Font: (Default) Times New Roman, 12 pt, Do not check spelling or grammar

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: 12 pt

Formatted: Font: 12 pt

Formatted: Font: Bold

Formatted: Font: 12 pt

Formatted: Font: 12 pt

Formatted: Font: 12 pt

Formatted: Font: 12 pt

Formatted: Font: Bold

Formatted: Justified, Line spacing: 1.5 lines

Formatted: Font: Bold

Formatted: Font: Not Bold

INTRODUCTION

Hypertension is one of the most common diseases worldwide and causes about 12% of deaths each year.[1] It is a risk factor for heart disease, mainly myocardial infarction, atherosclerosis (i.e., hardening of the arteries), heart failure, and stroke.[2] The angiotensin-converting enzyme (ACE) plays an essential role in hypertension management. It converts angiotensin I into angiotensin II in the kidneys (renin-angiotensin-aldosterone system) and activates bradykinin.[3] Skeggs ~~et al~~*et al*. first explained ACE's mechanism of action in 1953-1956.[4,5] Some kinds of synthetic ACE inhibitors, such as captopril, lisinopril, ramipril, enalapril, fosinopril, and zofenopril, have been widely used for the treatment of hypertension. However, studies of ACE inhibitor active compounds from natural products (mainly plant resources) continue because they have potential secondary metabolite content and fewer side effects.[5,6,7] ~~*In vitro*~~*In vitro* ACE inhibitory activity assay is a valid assay method for discovering drugs from active compounds found in natural products.[8]

Some studies have reported medicinal plants that exhibit potential antihypertensive effects.[2,5,7,9,10,11] Therefore, advanced research into finding other sources of natural products is needed. Various plants have been traditionally used to control blood pressure or hypertension. One of them is *Phyllanthus niruri* from the Euphorbiaceae family, known locally in Indonesia as 'Meniran.'[12] This plant can be found in tropical and subtropical climates including Indonesia and has a long history of ethnomedicinal or traditional use worldwide. Some studies have reported that aerial part of this plant has various pharmacological properties: hepatoprotective,[13] antiplasmodial,[14] antihyperalgesic,[15] antioxidant,[16] anti-inflammatory,[16,17] anti-gastric ulcer,[17] immunostimulator,[18] diuretic,[19] prostate cancer treatment,[20] and hair growth stimulant.[21] Scientific information related to the phytochemical constituents of this plant was described in detail by Kaur ~~et al~~*et al*. in 2017; it contains alkaloids, polyphenols, tannins, flavonoids, lignans, terpenoids, anthocyanins, saponins, and coumarins.[22] Methanol, n-hexane, and aqueous extracts of *P. niruri* were reported to have the inhibitory activity on angiotensin-converting enzymes (ACE).[23] However, an active compound from this plant that can be used as an ACE inhibitor has not been reported. In this study, four active compounds which could potentially act as ACE inhibitors were isolated and identified from *P. niruri*, and a molecular docking study was performed to predict the mechanism of action and interactions between the ligands (i.e., active compounds) and a macromolecule.

Formatted: Space After: 8 pt, Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Font: (Default) Times New Roman, 12 pt

Formatted: Superscript

Field Code Changed

Formatted: Superscript

Formatted: Superscript

Field Code Changed

Formatted: Superscript

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

MATERIALS AND METHODS

Plant Samples and Collection

The aerial parts of *P. niruri* were purchased in Banten Province, Indonesia and were authenticated by the Indonesia Institute of Sciences, Research Center of Biology, Cibinong–Bogor, West Java, Indonesia. The voucher specimen was deposited at the Laboratory of Pharmacognosy–Phytochemistry, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.

Chemical Reagents

Some chemicals used in this study, including n-hexane, ethyl acetate, chloroform, n-butanol, and acetone, were purchased from PT SmartLab Indonesia, Indonesia. Angiotensin-converting enzyme (ACE) and hippuryl-L-histidyl-L-leucine (HHL) substrates were purchased from Sigma Aldrich, USA. Captopril was acquired from PT Kimia Farma, Indonesia. Hydrochloric acid, sodium carbonate, potassium dihydrogen phosphate, sodium hydroxide, silica gel 60 H, silica gel TLC plate GF_{254}, and preparative TLC plates were purchased from Merck, Germany. Sephadex LH-20 was obtained from Amersham Bioscience, Sweden.

Apparatus

Apparatuses used in the study include a rotary vacuum evaporator (Buchi, Germany), micropipettes 100-1000 µl (Eppendorf, Germany), a UV-VIS spectrophotometer (Shimadzu, Japan), a UPLC-Qtof HR-MS XEV^{otm} mass spectrometer (Water, Milford, MA, USA), a FT-IR (Waltham, MA, USA), an ^{1}H-NMR and ^{13}C-NMR (JEOL JNM, Japan), a microplate reader (BioTek Elx808, USA), and multichannel pipettes (Thermo Scientific).

Extraction and Isolation

The powdered herb was macerated with 80% methanol and filtered. The same procedure was repeated three times. The organic layer was combined and concentrated using a rotary vacuum

Formatted: Line spacing: 1.5 lines

Formatted: Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Font: 12 pt

Formatted: Font: 12 pt

Formatted: Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

evaporator and then dried to give 476 g of methanolic extract. The extract (450 g) was dispersed in warm water and n-hexane was added. The n-hexane layer was collected and dried using a rotary vacuum evaporator to obtain the n-hexane fraction. Partitioning was continued by adding ethyl acetate and then n-butanol. The organic layers were evaporated to give ethyl acetate and n-butanol fractions. The n-hexane (19.28 g) and ethyl acetate (5 g) fractions were subjected to column chromatography using silica gel 60 as a stationary phase. n-Hexane and ethyl acetate fraction were eluted with n-hexane: ethyl acetate with a polarity gradient from 100–10%, followed by ethyl acetate: methanol with a gradient from 100–10%. Eighty-one 100 ml fractions were collected. The ethyl acetate fraction was subjected to silica gel column chromatography and eluted with n-hexane: ethyl acetate eluent (5:5), and 24 fractions were collected every 100 ml for each fraction. The n-butanol fraction was subjected to column chromatography with Sephadex LH-20. The sample was eluted with methanol: water with several comparison gradients from 50 to 100%. Two hundred and twenty fractions of 20 ml for each fraction were collected. Elution and fractionation were controlled by TLC under ultraviolet (UV) light at 254 nm and 366 nm. Similar fractions were combined according to their purities to give 15 for an n-hexane fraction (FH_A–FH_O), 5 for ethyl acetate (FE_A–FE_E) fraction, and 6 for an n-butanol fraction (FB_A–FB_F). Compound **1**, Compound **2**, Compound **3**, and Compound **4** were obtained from FH_E, FH_G, FE_C, and FB_C, respectively, after re-crystallization.

Structure Elucidation of Isolated Compounds

The structure of the isolated compounds was determined by analyzing spectroscopic data from UV-VIS, Fourier–Transform infrared (FT-IR), mass spectrometry (MS), ^{1}H-NMR, ^{13}C-NMR, and NMR-2D that covered HMQC and HMBC spectra.

Angiotensin Converting Enzyme (ACE) Inhibition Assay

The inhibitory effect was analyzed ~~*in vitro*~~*in vitro* via spectrophotometry, which measured the formed hippuric acid (HA). Hippuryl-L-histidyl-L-leucine (HHL) was catalyzed with ACE to form HA and L-histidyl-L-leucine. The sample's ACE inhibitory activity was determined according to Kurniawan ~~*et al*~~*et al*. (2016) which was based on the strategy developed by Cushman and Cheung (1971).[24,25] Briefly, 50 µl of the sample solution was added to 50 µl of 5 mM HHL as the substrate, it was vortexed for a few seconds to achieve homogenization, 100 µl ACE solution (0.025 U/ml) was added, and then it was incubated at 37ºC for 90 min~~utes~~.

Formatted: Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Font: 12 pt

Formatted: Font: 12 pt

Formatted: Font: 12 pt

Formatted: Font: 12 pt

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

The reaction was stopped by the addition of 250 µl 1N HCl. Formed HA was extracted with 1.5 ml ethyl acetate followed by centrifugation for 10 min and evaporated. HA was dissolved in 3 ml of ionized water, and the absorbance was measured at 228 nm.

Molecular Docking Studies

In silico molecular docking studies were conducted using a computer with core i7 processor, and Auto dock ZN was applied based on the previous study.[26] The crystal structure of the human angiotensin-converting enzyme in complex with native ligand lisinopril (PDB id: 1O86) was downloaded from http://www.rcsb.org/pdb/explore.do?structureId=1O86. Ligands were created manually in a 2D format in Marvin Sketch. AutoDockZn was employed for calculations in the molecular docking studies using a Lamarckian genetic algorithm between the flexible ligand and rigid receptor, a population size of 300, a maximum of 250,000 generations, and 2,500,000 evaluations for 100 GA runs. The root means square deviation was tolerated to below 2.0 Å for the clustering of docking results. The ligands' two-dimensional structure was visualized by LigandScout. Ligand-residue interactions were observed by LigPlot software.

RESULTS AND DISCUSSION

One cardiovascular risk for diabetic patients is hypertension. In this study, ACE inhibition as a hypertension mechanism was analyzed by measuring the absorbance of hippuric acid as the product of the reaction between HHL and ACE that was not inhibited by the sample. The positive result of ACE inhibition analysis is consistent with a previous study which found that a methanol extract of *P. niruri* inhibits the activity of ACE.[23]

Isolation and Identification of compounds from *P. niruri*

Each fraction was isolated using column chromatography; analyzing its inhibitory effect on ACE resulted in four compounds (as can be seen in Table 1). Specific results regarding each compound are as follows: 203.1 mg of Compound **1** and 78.5 mg of Compound **2** contained hexane fractions while 182.1 mg of Compound **3** was from the ethyl acetate fraction, and 10.9 mg of Compound **4** was from n-butanol.

Compound **1:** The FTIR spectrum of Compound **1** (crystal-like white needle) showed asymmetric =C-H- (2901.04 cm^{-1}), C-O ester (1259.56, 1026,16 cm^{-1}), and a H-C=C-H

Formatted: Line spacing: 1.5 lines

Field Code Changed

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Field Code Changed

Formatted: Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

aromatic ring bond (3055.3, 1639.5, 1506.4, 1425.4 cm^{-1}). The molecular weight [M^+] = 430.2 and molecular formula $C_{24}H_{30}O_7$ were obtained using GC-MS. Next, ^{1}H-NMR and ^{13}C-NMR were performed using CD_3OD, and the proton signals were obtained at 3.3 ppm (6H, *s*), 3.84, 3.86 (6H, *s*), and 3.80 ppm (3H, *s*).

Compound **2:** The FTIR spectrum of Compound **2** (crystal-like white needle) had a similarity to Compound 1 because it also showed the asymmetric =C-H- (2868.24 cm^{-1}), C-O ester (1236.41, 1141.9, 1167.18, 1026.16 cm^{-1}), and H-C=C-H aromatic ring bond (1587.47, 1508.38 cm^{-1}). Via the GC-MS study, the molecular weight [M^+] 418 and the molecular formulation $C_{24}H_{34}O_6$ was obtained. ^{1}H-NMR and ^{13}C NMR analyses were performed using $CDCl_3$, and the proton signals were received at 6.74 ppm (2H, *d*), 6.64 ppm (2H, *dd*), 6.61 ppm (2H, *d*), 3.85 ppm (6H, *s*), 3.8 ppm (6H, *s*), 3.2–3.3 ppm (10H, *m*), 2.6–2.7 ppm (4H, *m*), and 2.03 ppm (2H, m).

Compound **3:** (solid creamy-colored amorphous) showed O-H (3365.9 cm^{-1}), C=O (1693.59), aromatic C=C (1616.4 cm^{-1}), and C-O bond (1263.42 cm^{-1}) based on the FTIR study. The GC-MS data showed that the molecular weight [M^+] was 184 with a molecular formula of C_8H_8O. ^{1}H-NMR and ^{13}C-NMR were subsequently performed using CD_3OD; the proton signals were obtained at 3.81 ppm (3H, *s*) and 7.04 (2H, *s*).

Compound **4:** (yellow crystal) showed O-H (3431.48, 3319.6 cm^{-1}, broad), C=O (1694.98 cm^{-1}), aromatic C=C (1597.11 cm^{-1}, 1506.46 cm^{-1}, 1548.23 cm^{-1}), and C-O bond (1203.62, 1062.81, 1012.66 cm^{-1}) from the FTIR study. The LC-MS data showed that the molecular weight [M^+Na] was 633 with a molecular formula of $C_{27}H_{30}O_{16}$. Then the ^{1}H-NMR and ^{13}C-NMR analyses were performed, and the proton signals were obtained at 7.67 ppm (1H, *d*), 7.64 ppm (1H, *dd*), 6.8 ppm (1H, *d*), 6.4 ppm (1H, *d*), 6.21 ppm (1H, *d*), 5.10 ppm (1H, *d*), 4.5 ppm (1H, *d*), 3.4 ppm (1H, *m*), 1.12 ppm (3H, *d*), and 3.27-3.80 ppm (glucose proton).

This study found four potential compounds to be developed as antihypertension. As can be seen in Table 2 showed a comparison of all compounds with literature compound based on previous studies.[16,22,27] Compound **1** was identified as hypophyllanthin with ($C_{24}H_{30}O_7$) (Table 2a), Compound **2** was identified as phyllanthin ($C_{24}H_{34}O_6$) (Table 2b), Compound **3** was identified as methyl gallate ($C_8H_8O_5$) (Table 2c), and Compound **4** was identified as quercetin 3-*O*-β-D-glucopyranosyl-(1’’’-6’’)-α-rhamnoside (Table 2d).

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Field Code Changed

Field Code Changed

Field Code Changed

Angiotensin Converting Enzyme (ACE) Inhibitory Assay

Value of ACE inhibitory activity (as % inhibition) from methanolic extract was 48.32%, n-hexane fraction of 43.54%, ethyl acetate fraction of 56.55%, and an n-butanol fraction of 76.99%, at each concentration of 125 µg/ml. Analysis of the inhibitory effect of ACE was done to methyl gallate and quercetin 3-*O*-β-D-glucopyranosyl-(1’’’-6’’)-α-rhamnoside compared to captopril as the positive control, as can be seen in Table 3.

Hypophyllanthin and phyllanthin are marker compounds for *P. niruri*, and the inhibition effect of ACE enzymes for these two compounds was less potent than captopril as a control. Among these four compounds, methyl gallate and quercetin 3-*O*-β-D-glucopyranosyl-(1’’’-6’’)-α-rhamnoside were the most likely to inhibit the activity of ACE enzymes actively.

Molecular Docking Studies

As can be seen in Table 4, demonstrated interaction of the ACE complex with the ligand (native ligand, positive control, and isolated compounds), free energy binding, and inhibition constant (µM) from the molecular docking studies results using the AutoDockZn program. Glu384, Glu162, Lys511, Tyr520, Val518, Asp377, Ala354, Tyr523, Glu411, His513, His353, His383, and His387 are binding sites of ACE. Lisinopril as a native ligand performs hydrogen bonding with Glu384 and Glu162 and has a hydrophobic interaction with Val518. The C–terminal carboxylate of lisinopril interacts with positively charged ions towards Lys511 and Tyr520 (shown in Figure 1).

Figure 2A shows the interaction of the ACE complex with native ligand lisinopril (PDB: 1O86) visualized by LigPlot software. Lisinopril performs hydrogen bonding with Glu384 and Glu162 and indicates a hydrophobic interaction with Val518. C–terminal carboxylate of lisinopril interacts with positively charged ions towards Lys511 and Tyr520.[28]

Figure 2B shows the interaction of captopril as a ligand or positive control with the ACE complex. This ligand gives free energy binding (-5.17 ΔG Kcal/mol) and performs hydrogen bonding with Glu384, has a hydrophobic interaction with Val518 and interacts with positively charged ions on Lys511 and Tyr520. The positive control acts ~~similar to~~like the native ligand.

Formatted: Line spacing: 1.5 lines

Formatted: Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Field Code Changed

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Font: 12 pt

In Figure 2C, hypophyllanthin gives the lowest free energy binding while demonstrated fewer contacts with the potential binding site. This compound exhibits hydrogen bonding with Lys511 (NZ atom, 2.84 Å). Tyr520 is an essential binding site for C-terminal carboxylate by performing an ionic interaction. In this study, Tyr520 performed a hydrophobic interaction with Compound 1 was rather than an ionic interaction. Ala354, which is known for carrying out hydrogen bonding, showed a hydrophobic interaction instead. His383 and His387 might also be accompanied by Glu411, are residues that bind to Zinc, and have zinc-coordinating behavior.[28] These residues performed hydrophobic interactions towards the ligand. Zinc forms a strong bonding with histidine and ligand. It is important to remember that zinc is material for catalytic activity of ACE.[29]

Phyllanthin also binds to Lys511 through hydrogen bonding (NZ atom, 3.32 Å) as can be seen in Figure 2D. This ligand performed hydrophobic contact with His383, His387, His353, and Glu411. Histidine, accompanied by Glu411, appeared in this interaction of ligand-residues. These residues bind to zinc, and zinc binds to the ligand. Essential residues that bind to the ligand were very limited in hypophyllanthin and phyllanthin.

Figure 2E demonstrates that methyl gallate has hypoglycemic activity by inhibiting the aldose reductase enzyme, thus reducing cardiovascular risk (e.g., hypertension) in diabetic patients. Compared to the two previous compounds, methyl gallate demonstrated more H-bonding with residues. One of the essential residues, His353, interacted with two oxygen atoms of methyl gallate (O atom, 3.00 Å, and O1 atom 2.93 Å). Glu384 was also involved in this hydrogen bonding interaction (OE2 atom, 2.74 Å). Ala354 displayed hydrophobic contact instead of binding to the nitrogen atom as shown on lisinopril. His383, His387, and Glu411 appeared once more in the visualization.

In Figure 2F, quercetin 3-*O*-β-D-glucopyranosyl-(1’’’-6’’)-α-rhamnoside showed the most interactions compared to the other structures and scored the best affinity. The residue of protein receptor mainly Tyr520 and Glu162 bound with the O8 atom (3.17 Å), OE atom (2.34 Å), and the OE1 atom (2.93 Å). These bindings were also demonstrated by the native ligand (lisinopril).[28] In this compound, zinc bound to His387, His383, Glu411, and the ligand.

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Field Code Changed

Field Code Changed

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Font: (Default) Times New Roman, 12 pt

Field Code Changed

Figure 2G, unlike other compounds, the aglycone of quercetin (Compound 4) did not bind to zinc, although the histidine and Glu411 bound to Zn. Aglycone of compound 4 created several interactions with essential residues of 1O86. Aglycone slightly had less interaction compared to quercetin 3-*O*-β-D-glucopyranosyl-(1’’’-6’’)-α-rhamnoside and placed as second lowest free energy binding. It performed hydrogen bonding with Lys511 (NZ atom, 2.99 Å, and 2.78 Å), Tyr520 (OH atom, 2.98 Å) which also demonstrated in lisinopril interaction. Ala354, Glu162, and Tyr523 showed hydrophobic interaction rather than bound to electronegative atoms (oxygen or nitrogen) as shown on the native ligand.

In silico molecular docking studies provides additional data of ACE inhibitors mainly by predicting interactions and binding sites. The ~~*in silico*~~*in-silico* method emphasizes ligand-residue interactions, thereby predicting the inhibitory activity of these compounds. Residues that played a vital role in this docking study were less involved than what we expected from the literature. After docking to an ACE complex macromolecule (PDB: 1O86), quercetin 3-*O*-β-D-glucopyranosyl-(1’’’-6’’)-α-rhamnoside demonstrated more interactions than lisinopril. ACE is a chloride-dependent zinc metalloendopeptidase. The abolition of zinc alters the activity toward chromophoric substrates furan acryloyl-Phe-Gly-Gly.[30] ACE activity was lost below pH 7.5 without the presence of zinc. In the presence of zinc, ACE remains active at pH 6.[31] Zinc plays a vital part as a catalytic component of ACE; it binds to His383, His387, Glu411 and oxygen atoms from the carboxylate group of Lisinopril.[28]

CONCLUSION

This study showed that Compound **3** (methyl gallate) and Compound **4** (quercetin 3-*O*-β-D-glucopyranosyl-(1’’’-6’’)-α-rhamnoside), are potential active compounds as ACE inhibitors from *P. niruri* herb. Also, molecular docking studies predicted that there are similar action mechanism and domain specificity interaction between native ligand and this compound with the ACE complex macromolecule.

ACKNOWLEDGMENT

This study was financially supported by Directorate of Research and Community Engagement, Universitas Indonesia via Hibah Tugas Akhir Mahasiswa Doktor (TADOK) 2018.

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Field Code Changed

Field Code Changed

Field Code Changed

Formatted: Font: 12 pt

Formatted: Line spacing: 1.5 lines

Formatted: Indent: First line: 0 cm, Line spacing: 1.5 lines

Formatted: Line spacing: 1.5 lines

CONFLICT OF INTEREST

All author declares that have no conflict of interest

PICTORIAL ABSTRACT



SUMMARY

- Meniran (*Phyllanthus niruri*) has a long history of the use in ethnic or traditional medicine worldwide.
- Four active compounds were isolated from an aerial part of *P. niruri* include hypophyllantin, phyllantin, methyl gallate, and quercetin 3-*O*-β-D-glucopyranosyl-(1'''-6'')-α-rhamnoside.
- IC_{50} value of these compounds, such as 0.180 µg/mL, 0.140 µg/mL, 0.015 µg/mL, and 0.086 µg/mL, respectively.
- *In silico* molecular docking method emphasizes ligand-residue interactions, thereby predicting the inhibitory activity of these compounds.
- After docking to an ACE complex macromolecule, quercetin 3-*O*-β-D-glucopyranosyl-(1'''-6'')-α-rhamnoside obtained more interactions than lisinopril.

ABBREVIATIONS USED

P. niruri: Phyllanthus niruri; ACE: angiotensin converting enzyme; HHL: hippuryl-L-histidyl-L-leucine; HA: hippuric acid; PDB: protein database; IC_{50}: 50% inhibition concentration; FH: n-hexane fraction; FE: ethyl acetate fraction; TLC: thin layer chromatography; UV-VIS: ultraviolet-visible; NMR: nuclear magnetic resonance; FTIR: Fourier–Transform infrared; MS: mass spectrometry; HMQC: Heteronuclear Multiple-Quantum Correlation; HMBC: heteronuclear multiple bond correlation; TADOK: Tugas Akhir Mahasiswa Doktor.

REFERENCES

1. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization; 2011.
2. Tabassum N, Ahmad F. Role of natural herbs in the treatment of hypertension. Pharmacogn Rev. 2011;5(9):30–40.
3. Atlas S. The renin-angiotensin-aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13:S9–20.
4. Skeggs LT, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med. 1957;106:439–53.
5. Ahmad I, Yanuar A, Mulia K, Mun'im A. Review of angiotensin-converting enzyme inhibitory assay: Rapid method in drug discovery of herbal plants. Pharmacogn Rev. 2017;11(21):1–7.
6. Barbosa-Filho JM, Martins VKM, Rabelo LA, Moura MD, Silva M, Cunha EVL, et al. Natural products inhibitors of the angiotensin-converting enzyme (ACE). A review between 1980 - 2000. Rev Bras Farmacogn. 2006;16(3):421–46.
7. Braga FC, Wagner H, Lombardi JA, de Oliveira AB. Screening the Brazilian flora for antihypertensive plant species for in vitro angiotensin-I-converting enzyme inhibiting activity. Phytomedicine. 2000;7(3):245–50.
8. Cushman D, Wang F, Fung W, Grover G, Harvey C, Scalese R, et al. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin-converting enzyme (ACE). Br J Clin Pharmacol. 1989;28:115–31.
9. Simaratanamongkol A, Umehara K, Noguchi H, Panichayupakaranant P. Identification of a new angiotensin-converting enzyme (ACE) inhibitor from Thai edible plants. Food Chem. 2014;165:92–7.
10. Daskaya-Dikmen C, Yucetepe A, Karbancioglu-Guler F, Daskaya H, Ozcelik B. Angiotensin-I-converting enzyme (ACE)-inhibitory peptides from plants. Nutrients. 2017;9(4).
11. Lacaille-Dubois MA, Franck U, Wagner H. Search for potential Angiotensin

Converting Enzyme (ACE) -inhibitors from plants. Phytomedicine. 2001;8(1):47–52.

12. Ranilla LG, Kwon YI, Apostolidis E, Shetty K. Phenolic compounds, antioxidant activity and in vitro inhibitory potential against key enzymes relevant for hyperglycemia and hypertension of commonly used medicinal plants, herbs and spices in Latin America. Bioresour Technol. 2010;101(12):4676–89.
13. Amin ZA, Alshawsh MA, Kassim M, Ali HM, Abdulla MA. Gene expression profiling reveals underlying molecular mechanism of hepatoprotective effect of *Phyllanthus niruri* on thioacetamide-induced hepatotoxicity in Sprague Dawley rats. BMC Complement Altern Med. 2013;13(1):160-270.
14. Ifeoma O, Samuel O, Itohan AM, Adeola SO. Isolation, fractionation and evaluation of the antiplasmodial properties of *Phyllanthus niruri* resident in its chloroform fraction. Asian Pac J Trop Med. 2013;6(3):169–75.
15. Moreira J, Klein-Júnior LC, Filho VC, Buzzi FDC. Anti-hyperalgesic activity of corilagin, a tannin isolated from *Phyllanthus niruri* L. (Euphorbiaceae). J Ethnopharmacol. 2013;146(1):318–23.
16. Fang SH, Rao YK, Tzeng YM. Anti-oxidant and inflammatory mediator's growth inhibitory effects of compounds isolated from *Phyllanthus urinaria*. J Ethnopharmacol. 2008;116(2):333–40.
17. Mostofa R, Ahmed S, Begum MM, Sohanur Rahman M, Begum T, Ahmed SU, et al. Evaluation of anti-inflammatory and gastric anti-ulcer activity of *Phyllanthus niruri* L. (Euphorbiaceae) leaves in experimental rats. BMC Complement Altern. 2017;17(1):267-77.
18. Muthulakshmi M, Subramani PA, Michael RD. Immunostimulatory effect of the aqueous leaf extract of *Phyllanthus niruri* on the specific and nonspecific immune responses of *Oreochromis mossambicus* Peters. Iran J Vet Res. 2016;17(3):200–2.
19. Udupa A, Sanjeeva, Benegal A, Prusty V, Kodancha G, Kumar M, et al. Diuretic activity of *Phyllanthus niruri* (Linn.) in rats. Health. 2010;2(5):511–2.
20. Unni R, Shah G, Snima KS, Kamath CR, Nair S, Lakshmanan V-K. Enhanced Delivery of *Phyllanthus Niruri* Nanoparticles for Prostate Cancer Therapy. J Bionanoscience. 2014;8(2):101–7.
21. Patel S, Sharma V, N SC, Thakur M, Dixit VK. Evaluation of hair growth promoting activity of *Phyllanthus niruri*. Avicenna J Phytomed. 2015;5(6):512–9.
22. Kaur N, Kaur B, Sirhindi G. Phytochemistry and pharmacology of *Phyllanthus niruri* L.: A Review. Phytother Res. 2017;31(7):980–1004.

23. Ueno H, Horie S, Nishi Y, Shogawa H, Kawasaki M, Suzuki S, et al. Chemical and pharmaceutical studies on medicinal plants In Paraguay. Geranin, an angiotensin-converting enzyme inhibitor from “Paraparai Mi” *Phyllanthus niruri*. J Nat Prod. 1988;5(2):357–9.
24. Kurniawan A, Saputri FC, Ahmad I, Mun’im A. Isolation of angiotensin-converting enzyme (ACE) inhibitory activity quercetin from *Peperomia pellucida*. Int J PharmTech Res. 2016;9(7):115–21.
25. Cushman D, Cheung H. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol. 1971;20(7):1637–48.
26. Santos-martins D, Forli S, Joa M, Olson AJ. AutoDock4Zn: An improved AutoDock force field for small-molecule docking to zinc metalloproteins. J Chem Inf Model. 2014;54:2371–9.
27. Maciel M, Cunha A, Dantas T, Kaiser C. NMR Characterization of bioactive lignans from *Phyllanthus amarus* Schum &. Ann Magn Reson. 2007;6(3):76–82.
28. Natesh R, Schwager SLU, Sturrock ED, Acharya KR. Crystal structure of the human enzyme – lisinopril complex. Nature. 2003;421(1995):1427–9.
29. Bünning P, Riordan JF. The Functional role of zinc in angiotensin-converting enzyme: implications for the enzyme mechanism. J Inorg Biochem. 1985;24:183–98.
30. Bünning P, Riordan JF. The role of zinc in angiotensin-converting enzyme. Isr J Chem. 1981;21:43–7.
31. Bünning P, Holmquist B, Riordan JF. Substrate specificity and kinetic characteristics of angiotensin-converting enzyme. Biochemistry. 1983;22:103–10.

Table 1: IUPAC name and chemical structures of isolated compounds from *P. niruri*.

No	Compound	IUPAC Name	Structure
1	Hypophyllanthin	9-(3,4-dimethoxyphenyl)-4-methoxy-7,8-bis(methoxymethyl)-6,7,8,9-tetrahydronaphtho[1,2-d][1,3]dioxole	
2	Phyllanthin	4,4'-(2,3-bis(methoxymethyl)butane-1,4-diyl)bis(1,2-dimethoxybenzene)	
3	Methyl Gallate	methyl 3,4,5-trihydroxybenzoate	
4	quercetin 3-*O*-β-D-glucopyranosyl-(1’’’-6’’)-α-rhamnoside	2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((3S,4S,5R,6S)-3,4,5-trihydroxy-6-((((1S,2S,3S,4S,5R)-2,3,4-trihydroxy-5-methylcyclohexyl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one	

Table 2: Chemical shift comparison of (a) hypophyllanthin and Compound 1, (b) phyllanthin and compound 2, (c) methyl gallate and compound 3, and (d) quercetin 3-*O*-rutinoside and compound 4.

2a. Chemical shift comparison of hypophyllanthin and Compound 1 ($CDCl_3$, 125 MHz).

Atom	^{13}C-NMR hypophyllanthin	^{13}C-NMR Compound 1
C-1	131.96	131.8
C-2	106.55	106.5
C-3	143.52	142
C-4	133.75	133.2
C-5	147.08	147
C-6	115.25	115.0
C-7	33.3	33.2
C-8	35.62	36.6
C-9	75.47	75.4
C-1’	138.15	138
C-2’	111.84	111.8
C-3’	148.85	148.5
C-4’	147.08	147.1
C-5’	110.79	110.6
C-6’	120.6	120.4
C-7’	42.08	41.8
C-8’	45.59	45.3
C-9’	71.87	71.7
C-9a & 9’a	58.98; 59.12	58.8
C-1”	101.33	101
C-3’a & 3a	55.63	55.8; 55.7
C-4’a	56.92	56.3

2b Chemical shift comparison of phyllanthin and compound 2 ($CDCl_3$, 125 MHz).

Atom	^{13}C-NMR phyllanthin	^{13}C-NMR Compound 2
C-3, 3’	148.7	148.8
C-4, 4’	147.1	147.2
C-1, 1’	133.6	133.7
C-6, 6’	121.0	121.2
C-2, 2’	112.2	112.2
C-5, 5’	111.0	111.0
C-9, 9’	72.6	72.7

C-9, 9'-OCH_3	58.7	58.9
C-3, 3', & 4, 4'-OCH_3	55.8	56.0 & 55.8
C-8. 8'	40.7	40.9
C-7, 7'	34.9	35.0

2c Chemical shift comparison of methyl gallate and compound 3 (CD_3OD, 125 MHz)

Atom C	δ methyl gallate	δ Senyawa 3
C-1	121.6	121.5
C-2, 6	110.2	110.1
C-3, 5	146.7	146.6
C-4	139.9	139.8
C-7 (C=O)	169.2	169.1

2d Chemical shift comparison of quercetin 3-*O*-rutinoside and compound 4 (CD_3OD, 125 MHz).

Atom	^{13}C-NMR quercetin 3-*O*-rutinoside	^{13}C-NMR compound 4
C-2	158.5	159.4
C-3	135.6	135.7
C-4	179.4	179.5
C-5	163.0	163.1
C-6	100.0	100.0
C-7	166.1	166.2
C-8	94.9	94.9
C-9	159.4	156.6
C-10	105.6	105.7
C-1'	123.6	123.6
C-2'	116.1	116.1
C-3'	145.8	145.9
C-4'	150.0	149.9
C-5'	117.7	117.7
C-6'	123.1	123.1
Glu C-1''	102.7	104.5
Glu C-2'' & 3''	75.0; 77.4	75.8 & 77.3
Glu C-4'', 5'' & 6''	70.8; 76.7; 67.9	71.4; 78; 68.6
Rha C-1''''	101.7	102.5
Rha C-2''''	71.2	72.1
Rha C-3''''	71.5	72.3
Rha C-4''''	72.8	74.0
Rha C-5''''	69.1	69.8
Rha C-6''''	18.6	17.9

Table 3: Angiotensin-converting enzyme (ACE) inhibition effect of isolated compounds from *P. neruri*.

Sample	ACE Inhibitory Activity IC_{50} (µg/mL)
Captopril	0.031
Compound 1 (hypophyllanthin)	0.180
Compound 2 (phyllanthin)	0.140
Compound 3 (methyl gallate)	0.015
Compound 4 (quercetin 3-*O*-β-D-glucopyranosyl-(1’’’-6’’)-α-rhamnoside)	0.086

Table 4: Recapitulation of ACE binding site docked, free energy binding, inhibition constant using Auto Dock Zn.

Ligand	Interaction of ACE binding site											Free Energy Binding (ΔG Kcal/mol)	Inhibition Constant (µM)
	Glu384	Glu162	Lys511	Tyr520	Val518	Asp377	Ala354	Tyr523	Glu411	His513	His353		
Lisinopril (native)	√	√	√	√	√	√	√	√	-	-	√	-8.53	$556.25x10^{-3}$
Captopril	√	-	√	√	√	-	√	√	-	-	√	-5.17	162.82
Hypophyllantin	-	-	-	-	√	-	-	-	-	-	-	-7.19	5.38
Phyllantin	-	-	-	-	√	-	-	√	-	-	-	-6.30	24.02
Methyl gallate	-	-	-	-	-	-	-	-	-	-	-	-4.81	229.35
quercetine 3-*O*-β-D-glucopyranosyl-(1’’’-6’’)-α-rhamnoside	-	-	-	-	-	-	-	√	-	√	√	-6.52	16.66
quercetine (aglycone of Compound 4)	-	√	√	√	-	√	√	-	-	-	-	-6.86	9.35

Formatted: Line spacing: 1.5 lines, Tab stops: 2.99 cm, Left

Formatted: Font: (Default) Times New Roman, 12 pt